Imagin Medical (“IME”) is a company focusing on the early detection of cancer, using its proprietary imaging solutions. Targeting bladder cancer, the 6th most prevalent cancer in the United States, Imagin incorporates advanced ultra-sensitive imaging technology developed at the Lawrence Livermore National Laboratory to allow surgeons to detect cancer during minimally invasive surgeries.
Imagin has completed development of the Alpha Prototype, an advanced combination of optical/light sensor technology, white light and near-infrared fluorescence that is estimated to be 100 times more sensitive than current systems. The Alpha Prototype will have the ability to expose the specifics of the cancer in less than 15 minutes versus the full hour required by conventional fluorescence systems. Resulting in superior imaging quality in a fraction of the time current systems. The Alpha Prototype is expected to increase the efficiency of the operating room and reduce healthcare costs by potentially enabling follow-up exams to be performed in physician’s office, saving patients money and increasing efficiency.
In addition, the surgeon will no longer need to switch back and forth between two images. The patented technology blends the white and blue light images into one, putting the cancer into context and enabling the surgeon to better visualize and resect the cancer.
There are several factors that make Imagin very attractive for investors. Imagin has patented and proprietary technology that's use is needed in today's environment of ever-increasing cases of cancer. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. Imagin's technology cannot be overstated. The earlier the detection of cancer, the better the chances of containing it.
Secondly, a company’s strength is often stated in the management and the advisory board. Imagin's Board of Directors is impressive in its ability to grow companies from the conceptual stage to commercialization. It is however, the Advisory Board that is very impressive in its presentation. Suited with four M.D.'s as Medical Advisors and a Ph.D. As the Technical Scientific Advisor, Imagin has established an advisory board that includes Dr. Messing, who has been recently honored by the American Urology Association (AUA) for improving the lives of those with bladder, prostate, kidney and testicular cancer for 35 years; Dr. Buckley, who developed and chaired the International Bladder Cancer Group (IBCG) from 2006 to 2016; and Dr. De Vere White who has been the multiple recipient of the “Best Doctors in America” title.
Another key aspect to take into consideration for IME, is the private placement that occurred back in October of 2017, is the type of investors the company was able to obtain. Investors in this Private Placement include urologists Dr. Stan Swierzewski, Chief of Surgery & Director of Urology at Holyoke Medical Center in Massachusetts, and Dr. Roger Buckley, Division Head of Urology at North York General Hospital in Toronto. This shows the confidence that Urologists have in the technology of IME, infact these are the same type of doctors that would be using the tech to detect early stage cancer.
Progress is being made corporately with IME. A release stated on January 22nd, outlines where subjects have been recruited and procedures are being coordinated for a 10-subject research study to optimize product performance with the University of Rochester. The entire study will be performed over a 9 month period, where previous bench-testing results will be validated. The feasibility will be aimed at showing the efficacy of the i/Blue Imaging System technology to potentially detect the bladder cancer in 15 minutes.
Overall, we feel the company is established to revolutionize the efficiency on how early stage bladder cancer is currently detected. It has a strong management and advisory team and it has a strong vote of confidence as shown by other Urologists investing in the $1mm private placement that occurred.
Forward Looking Statements: This article may contain "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, estimates and projections as of the date of the content is published on this website. Wherever possible, words such as "anticipate", "believe", "expects", "intend" and similar expressions have been used to identify these forward- looking statements. Information in this article has been furnished for your information only, is accurate at the time of posting, and may be superseded by more current information. Except as required by law, we do not undertake any obligation to update the information, whether as a result of new information, future events or otherwise. This article should not be considered as personal financial advice. Full disclosure: Equity Insight Inc. is a paid client of Imagin Medical